The Journal of Experimental Medicine
VeriKine-HS Human Interferon-Beta Serum
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1291K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guidotti, L. G.
Right arrow Articles by Chisari, F. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guidotti, L. G.
Right arrow Articles by Chisari, F. V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1999/5/1555/ $5.00
The Journal of Experimental Medicine, Volume 189, Number 10, May 17, 1999 1555-1564

Articles

Noncytopathic Clearance of Lymphocytic Choriomeningitis Virus from the Hepatocyte

Luca G. Guidotti*, Persephone Borrow{ddagger}, Amy Brown*, Heike McClary*, Rick Koch*, and Francis V. Chisari*

From the * Department of Molecular and Experimental Medicine and the {ddagger} Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037

We have previously shown that interferon and tumor necrosis factor noncytopathically abolish hepatitis B virus (HBV) replication from the hepatocyte and kidney tubular epithelial cells in vivo. Here we show that a persistent lymphocytic choriomeningitis virus (LCMV) infection is cleared from the hepatocyte noncytopathically when the same cytokines are induced in the liver by antigen-nonspecific stimuli. These results indicate that, like HBV, LCMV is also susceptible to intracellular inactivation by cytokine-induced antiviral mechanisms that are operative in the hepatocyte. In contrast, LCMV is not cleared from intrahepatic nonparenchymal cells or splenocytes, indicating that, unlike the hepatocyte, these cells do not produce the factors required to inactivate LCMV. Antiviral mechanisms like these may have evolved to maintain the functional integrity of vital organs in the face of massive infection.

Key Words: lymphocytic choriomeningitis virus • noncytopathic clearance • hepatocyte • cytokines

Address correspondence to Luca G. Guidotti, The Scripps Research Institute, Department of Molecular and Experimental Medicine, 10550 North Torrey Pines Rd., La Jolla, CA 92037. Phone: 619-784-2758; Fax: 619-784-2960; E-mail: guidotti{at}scripps.edu

P. Borrow's present address is The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire RG20 7NN, UK.

Abbreviations used: APP, acute phase protein; ARM, Armstrong strain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HBV, hepatitis B virus; LCMV, lymphocytic choriomeningitis virus; NP, nucleoprotein; 2'5' OAS, 2',5'-oligoadenylate synthetase; sALT, serum alanine aminotransferase.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS